Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG’s Feraheme Expansion Strategy Delayed For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has extended by three months its review of a sNDA for the I.V. iron product that would expand the drug’s use into a far broader patient population.

Advertisement

Related Content

FDA Trial Design Challenge: Does Same Indication Demand Same Kind Of Study?
A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron
ESRD Market Snapshot: The Price Has To Be Right
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG Pharmaceuticals: Enough Irons In The Fire?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS074905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel